Lexicon Pharmaceuticals (LXRX) Revenue (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 16 years of Revenue data on file, last reported at $21.1 million in Q1 2026.

• On a quarterly basis, Revenue rose 1572.11% year-over-year to $21.1 million in Q1 2026; TTM through Mar 2026 was $69.6 million, a 123.12% increase from a year earlier, with the FY2025 full-year figure at $49.8 million, up 60.24% from the prior year.
• Revenue for Q1 2026 stood at $21.1 million, up from $5.5 million in the prior quarter.
• Over the last five years, Revenue for LXRX reached as high as $28.9 million in Q2 2025 and fell as low as $35000.0 in Q2 2022.
• Historically, Revenue has averaged $7.9 million across 5 years, with a median of $1.6 million in 2024.
• Across the five-year window, Revenue surged 3366.58% in 2024 and sank 79.31% in 2025, its largest moves.
• Year by year, Revenue stood at $35000.0 in 2022, then surged by 2088.57% to $766000.0 in 2023, then jumped by 3366.58% to $26.6 million in 2024, then sank by 79.31% to $5.5 million in 2025, then soared by 284.16% to $21.1 million in 2026.
• Per Business Quant data, the three most recent Revenue figures were $21.1 million in Q1 2026, $5.5 million in Q4 2025, and $14.2 million in Q3 2025.